Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500381 · ClinicalTrials.gov registry record · Phase 3
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 3 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
NCT02500381 is a Phase 3 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 228 participants.
The verdict
NCT02500381, a Phase 3 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
Interventions
- DRUG Placebo
- DRUG SRP-4053
- DRUG SRP-4045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2025-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500381
The ClinicalTrials.gov registry entry for NCT02500381 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02500381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02500381 about?
NCT02500381 is a clinical study titled "Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)". The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
What is the current status of trial NCT02500381?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2016-09-28. Estimated completion is 2025-10-16.
What interventions are being tested in trial NCT02500381?
The interventions under investigation include: Placebo (DRUG), SRP-4053 (DRUG), SRP-4045 (DRUG).
Who is sponsoring clinical trial NCT02500381?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.